Supported Approaches
PREVENT supports these approaches to prevention:
- Immunoprevention (e.g., vaccines for cancers associated or not associated with infectious agents, immunomodulatory agents)
- Chemoprevention (e.g., novel mechanisms, novel agents, anti-inflammatory approaches, drug repurposing, toxicity reduction strategies by dose and scheduling optimization, alternative routes of drug administration or combination regimens)
- Clinically translatable biomarkers of tumor progression and/or prevention efficacy
PREVENT Cycles 1 through 17
A total of 101 projects have been implemented: 61 chemoprevention projects, 32 immunoprevention projects, and 8 biomarker projects.
Jump to: Bladder | Breast | Cervical & Other HPV Cancers | Colon | Lung | Ovary | Pancreas | Prostate | Other Cancers | GMP Production
| Cancer Type | Type of Agent | Project Title | Project Number | Applicant Principal Investigator (PI) | Applicant PI Organization |
|---|---|---|---|---|---|
| Bladder | Chemoprevention | Evaluation of Agents/Protocols that Inhibit Two Major Pathways Involved in Human Urinary Bladder Cancer (PI3K, EGFR) and Protocols to Reduce Their Toxicity | 261201500036I- 0-26100002-1 |
Grubbs, Clinton J., Ph.D. | University of Alabama at Birmingham |
| Prevention of Urinary Bladder Cancer with Two "Clinically-Ready" Agents (Everolimus and Naproxen) When Administered in Combination | 261201500036I- 0-26100008-1 |
Grubbs, Clinton J., Ph.D. | University of Alabama at Birmingham | ||
| Preclinical Development of Newly Formulated Chemopreventive Agent 4-methylumbelliferone Prodrug | 261201500036I- 0-26100010-1 |
Lokeshwar, Vinata, Ph.D. | Georgia Regents University | ||
| Evaluation of Two Different Classes of Compounds (STAT3 Inhibitors and SERMs) for Prevention of Urinary Bladder Cancers | 75N91019D00019- 0-759101900130-1 |
Grubbs, Clinton J., Ph.D. | University of Alabama at Birmingham | ||
| Immunoprevention | Multi-antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer | 261201500036I- 0-26100006-1 |
Disis, Mary (Nora) L., M.D., M.S. | University of Washington | |
| Further Development of Multi-antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer | 261201500036I- 0-26100011-1 |
Pipeline Project (Original Applicant: Disis, Mary (Nora) L., M.D., M.S.) | Pipeline Project | ||
| Breast | Chemoprevention | Evaluation of GLG-302, a STAT3 Antagonist, in the Prevention of Mammary Cancer | 261201200021I- 0-26100004-1 |
Lovell, Michael W., Ph.D. | GLG Pharma, LLC |
| Efficacy of Metformin in the Methylnitrosourea-induced Model of ER+ Mammary Carcinogenesis when Animals are Placed on Different Diets: Standard Diet, High Fat Diet, and High Fructose Diet | 261201200021I- 0-26100005-1 |
Grubbs, Clinton J., Ph.D. | University of Alabama at Birmingham | ||
| Evaluation of the Prevention by ACTOPLUS/MET (Pioglitazone and Metformin) of ER+ and ER- Mammary Cancers Occurring in Rodents on a High-Fat Diet | 261201200021I- 0-26100006-1 |
Grubbs, Clinton J., Ph.D. | University of Alabama at Birmingham | ||
| Effect of Bazedoxifene Either Alone or in Combination with an Aromatase Inhibitor or Conjugated Estrogens (CE) in the Prevention of Mammary Cancers | 261201200021I- 0-26100007-1 |
Grubbs, Clinton J., Ph.D. | University of Alabama at Birmingham | ||
| Evaluation of the Cancer Prevention Efficacy of GLG-302 | 261201500036I- 0-26100003-1 |
Pipeline Project (Original Applicant: Lovell, Michael W., Ph.D.) | Pipeline Project | ||
| Support for Endoxifen Gel Clinical Development | 261201500024I- 0-26100002-1 |
Khan, Seema A., M.D. | Northwestern University | ||
| Examination of HJC0152 as a Putative Modulator of Glucose and Energy Metabolism for Mammary Cancer | 261201500018I- 0-26100002-1 |
Shen, Qiang, M.D., Ph.D. | MD Anderson Cancer Center | ||
| Targeted Casein Kinase 1d (CK1d) Inhibition as a Breast Cancer Prevention Strategy | 261201500018I- 0-26100005-1 |
Aldaz, C. Marcelo, M.D., Ph.D. | MD Anderson Cancer Center | ||
| Evaluation of "Clinical-Ready" Agents (Bazedoxifene and Lapatinib) in Combination for the Prevention of ER+ and ER- Mammary Cancers | 261201500036I- 0-26100005-1 |
Grubbs, Clinton J., Ph.D. | University of Alabama at Birmingham | ||
| Targeting the mTOR Pathway for the Prevention of Breast Cancer | 261201500018I- 0-26100006-1 |
Brown, Powel H., M.D., Ph.D. | MD Anderson Cancer Center | ||
| Evaluation of STAT3 Antagonists in the Prevention of Mammary Cancer | 261201500036I- 0-26100007-1 |
Pipeline Project (Original Applicant: Lovell, Michael W., Ph.D.) | Pipeline Project | ||
| Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer | 261201500018I- 0-26100008-1 |
Mazumdar, Abhijit, Ph.D. | MD Anderson Cancer Center | ||
| RANK Ligand Inhibition: A Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer | 261201500018I- 0-26100009-1 |
Lindeman, Geoffrey, Ph.D., FRACP, M.B.B.S. | University of Melbourne | ||
| Use of Rosemary Extract/Carnosic Acid for Prevention of Ductal Carcinoma in situ | Pending | Behbod, Fariba, PharmD, Ph.D. | University of Kansas Medical Center | ||
| Biomarker | Chemopreventive Effects in Both Standard Chow Diets and High Fat Diets of Known Positive and Negative Chemopreventive Agents Employing Both High Risk (But Histologically Normal) Mammary Epithelium and Mammary Cancers Including Correlative Biomarkers | N/A | Grubbs, Clinton J., Ph.D. | University of Alabama at Birmingham | |
| Blood-based Biomarkers of Obesity-induced Breast Inflammation | 261201200018I- 0-26100003-1 |
Dannenberg, Andrew J., M.D. | Weill Cornell Medicine | ||
| Immunoprevention | AAV1-Plac1 Vaccine Platform for Cancer Prevention | 261201200018I- 0-26100002-1 |
Glazer, Robert I., Ph.D. | Georgetown University | |
| Efficacy of a Multi-antigen Vaccine in the Prevention of MNU-induced Mammary Cancers ER Positive in Female SD Rats | 261201200021I- 0-26100002-1 |
Grubbs, Clinton J., Ph.D. | University of Alabama at Birmingham | ||
| Development of a Multi-antigen, Multi-peptide Vaccine based on Gene Expression Information to Prevent Triple Negative Breast Cancer in a Mouse Model | 261201500037I- 0-26100007-1 |
You, Ming, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | ||
| Evaluating Whether a Concurrent Retinoid X Receptor Agonist Can Enhance the Efficacy of the HER2-IGFBP2-IGF1R Vaccine in Eliminating Existing Ductal Carcinoma In Situ and Preventing Progression of Invasive Breast Cancer | 261201500036I- 0-26100009-2 |
Stanton, Sasha E, M.D., Ph.D. | University of Washington | ||
| Further development of a Multi-antigen, Multi-peptide Vaccine Based on Gene Expression Information to Prevent Triple Negative Breast Cancer in a Mouse Model | 261201500037I- 0-26100008-1 |
Pipeline Project (Original Applicant: You, Ming, M.D., Ph.D.) | Pipeline Project | ||
| Cancer Prevention by Vaccination Against Induced Antigens | 75N91019D00021- 0-759101900132-1 |
Hanash, Sam M., M.D., Ph.D. | MD Anderson Cancer Center | ||
| Cervical and Other HPV Cancers | Chemoprevention | Nonclinical Safety, Toxicokinetic, and Stability Evaluation of Bioresponse Diindolylmethane Vaginal Cream for Topical Treatment of Cervical Intraepithelial Neoplasia (CIN) | 261201200025I- 0-26100002-1 |
Zeligs, Michael, M.D. | BioResponse, LLC |
| Immunoprevention | Safety Evaluation of pNGVL4a-CRT-E6E7L2 (detox) Recombinant DNA Vaccine in Mice | 261201200026I- 0-26100002-1 |
Roden, Richard B.S., Ph.D. | Johns Hopkins | |
| Support for HPV16L1/RG1 Chimeric Virus-like Particle Vaccine Clinical Development | 261201500026I- 0-26100002-1 |
Kirnbauer, Reinhard, M.D. | Medical University Vienna (MUV) | ||
| Colon | Chemoprevention | Preclinical Development of mPGES-1 and 5-LOX Selective Inhibitors for Chemoprevention | 261201200020I- 0-26100004-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences |
| Efficacy of Aspirin and Naproxen (Short-term Frequent Dosing) in Colorectal Cancer Models | 261201200020I- 0-26100002-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | ||
| Combination of Aspirin and Omeprazole for Colorectal Cancer Chemoprevention | 261201200020I- 0-26100003-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | ||
| NSAID Chemoprevention in Colorectal Cancer | 261201200020I- 0-26100005-1 |
Fishel, Richard, Ph.D. | Ohio State University | ||
| Efficacy of Eldecalcitol (ED-71) in Colorectal Cancer Prevention in ApcMin-FCCC/+Mouse Model | 261201200015I- 0-26100005-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | ||
| Prevention of Colorectal Cancer by ONC201 | 261201500038I- 0-26100006-1 |
El-Deiry, Wafik, M.D., Ph.D., F.A.C.P. | Fox Chase Cancer Center | ||
| Combination of Aspirin or Naproxen with Omeprazole for Colorectal Cancer Chemoprevention with Clinically Relevant Doses | 261201500038I- 0-26100003-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | ||
| Determination of Dosing Regimens of Erlotinib in Combination with Sulindac for Prevention of Colorectal Cancer While Reducing Agent Toxicity | 261201500018I- 0-26100004-1 |
Dashwood, Roderick H., Ph.D., M.S. | Texas A&M University | ||
| Chemoprevention of Colorectal Cancer with Olmesartan Medoxomil | 261201500038I- 0-26100011-2 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | ||
| A Novel Non-COX Inhibitory Sulindac Derivative for Colorectal Cancer Chemoprevention with Selective PDE10 and Wnt/b-Catenin Inhibitory Activity | 261201500032I- 0-26100003-1 |
Piazza, Gary A., Ph.D. | University of South Alabama Mitchell Cancer Institute | ||
| LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Investigational New Drug (IND)-directed GLP Toxicology Studies | 261201500024I- 0-26100005-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | ||
| Optimization of Dosing Regimens of Sulindac in Combination with Erlotinib for Small Intestinal and Colon Cancer Prevention | 75N91019D00021- 0-759101900130-1 |
Pipeline Project (Original Applicant: Dashwood, Roderick H., Ph.D., M.S.) | Pipeline Project | ||
| TP-252: A Longer Acting Eicosapentaenoic Acid (EPA) Analogue for Colorectal Cancer Chemoprevention | 75N91019D00019- 0-759101900132-1 |
Rosenberg, Daniel W., Ph.D. | University of Connecticut School of Medicine | ||
| Biomarker | Effect of a Chemopreventive Agent on the Fecal Metabolite Profile in Intestinal Neoplasia | N/A | Gross, Steven, Ph.D. | Cornell University | |
| Molecular Heterogeneity of Inflammation and Growth Factor Pathways in Sporadic and Syndromic Colon Cancers: Implications for Prevention and Therapeutic Trials | 261201200013I- 0-26100008-1 |
Bernard, Philip S., M.D. | University of Utah | ||
| Immunoprevention | Characterization of Potential Antigens for Immunization Against Colon Cancer and Testing Multivalent Tumor Vaccines in Min Mice | 261201200013I- 0-26100003-1 |
Broussard, Elizabeth, M.D. | University of Washington | |
| Anti-Fusobacterium nucelatum Vaccine for Colorectal Cancer Immunoprevention | 261201500039I- 0-26100004-1 |
Lipkin, Steven M., M.D., Ph.D., FACMG | Weill Cornell Medicine | ||
| Testing of Combination Immuno- and Chemoprevention Strategies for Lynch Syndrome | 261201500039I- 0-26100003-1 |
Lipkin, Steven M., M.D., Ph.D., FACMG | Weill Cornell Medicine | ||
| Immunogenic effects of NSAIDs with and without a vaccine in colon cancer prevention | 261201500036I- 0-26100004-1 |
Disis, Mary (Nora) L., M.D., M.S. | University of Washington | ||
| Frameshift Peptide Vaccine for the Prevention of Lynch Syndrome-associated Gastrointestinal Cancer | 261201500039I- 0-26100005-1 |
Pipeline Project (Original Applicant: Lipkin, Steven M., M.D., Ph.D., FACMG) | Pipeline Project | ||
| Further Development of Colovac, a Multi-antigen Multi-peptide Vaccine, for Colon Cancer Prevention | 75N91019D00019- 0-759101900131-1 |
Pipeline Project (Original Applicant: Disis, Mary (Nora) L., M.D., M.S.) | Pipeline Project | ||
| Lung | Chemoprevention | In Vivo Evaluation of a Chemopreventive Agent, Ciclesonide, in Mouse Lung Tumor Model by Inhalation | 261201200013I- 0-26100002-1 |
Sharma, Sheela, Ph.D., M.S. | Integrated Laboratory Systems, Inc. |
| Anti-inflammatory Effects of Fixed Dose Combination of Pioglitazone and Metformin for Lung Cancer Prevention | 261201200015I- 0-26100002-1 |
Wattenberg, Lee W., M.D. | University of Minnesota | ||
| Effects of Weekly or Intermittent Dosing Regimens of EGFR, MEK and PI3K Inhibitors in Mouse Models of Lung Cancer | 261201200013I- 0-26100007-2 |
Wang, Yian, M.D., Ph.D. | Washington University at St. Louis | ||
| Lung Cancer Chemoprevention by microRNA Delivery | 261201500037I- 0-26100005-1 |
Izzotti, Alberto, M.D., Ph.D. | University of Genoa | ||
| Chemoprevention with Aerosolized Bexarotene in Mouse Models of All Three Major Subtypes of Lung Cancer: Adenocarcinoma, Squamous Cell Carcinoma and Small Cell Lung Cancer | 261201200020I- 0-26100007-1 |
Wang, Yian, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | ||
| Support for Aerosol Development of Bexarotene | 261201500024I- 0-26100004-1 |
Pipeline Project (Original Applicant: Wang, Yian, M.D., Ph.D.) | Pipeline Project | ||
| Chemoprevention with Aerosolized Let-7 microRNA in Mouse Models of Non-Small Cell Lung Cancer (Adenocarcinoma and Squamous Cell Carcinoma) | 75N91019D00020- 0-759101900130-1 |
You, Ming, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | ||
| Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung and Breast Cancer | 75N91019D00021- 0-759101900131-1 |
Aldaz, C. Marcelo, M.D., Ph.D. | MD Anderson Cancer Center | ||
| Biomarker | Modulation of Cigarette Smoke-induced Alterations of microRNA Expression and Lung Tumors in Mice Treated with Aspirin and Naproxen | 261201200015I- 0-26100003-1 |
De Flora, Silvio, M.D. | University of Genoa | |
| Effects of Chemopreventive Agents on Biomarkers Related to Lung Tumorigenesis: Alterations in "At Risk" Histogologically Normal Lung and Lung Lesions | 261201200015I- 0-26100004-1 |
You, Ming, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | ||
| Modulation of miRNA Expression in Blood or Other Biological Fluids Compared with Tissue Levels in Mice Exposed to Cigarette Smoke and/or with NSAIDs | 261201200015I- 0-26100006-1 |
Izzotti, Alberto, M.D., Ph.D. | University of Genoa | ||
| Examination of Exosomal miRNAs as Potential Biomarkers for Chemopreventive Efficacy in Mouse Models of Lung Squamous Cell Carcinoma | 261201500037I- 0-26100003-1 |
You, Ming, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | ||
| Immunoprevention | Use of TERT Vaccine in Prevention of Lung Cancer in Animal Models | 261201200013I- 0-26100006-1 |
You, Ming, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | |
| Multi-antigen Vaccine for Lung Cancer Prevention | 261201200013I- 0-26100009-1 |
Disis, Mary (Nora) L., M.D., M.S. | University of Washington | ||
| Development of Multiantigen Vaccines to Prevent the Development of Lung Adenocarcinomas Driven by either K-RAS or EGFR Oncoproteins in Mice | 261201500037I- 0-26100002-1 |
You, Ming, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | ||
| Rational Design and Development of a Multi-antigen Multi-peptide Vaccine Based on Genomic Information to Prevent Lung Cancer Initiation and Progression | 261201500037I- 0-26100004-1 |
You, Ming, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | ||
| EGFR and KRAS Vaccine to Prevent Lung Cancer | Pending | You, Ming, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | ||
| Ovary | Chemoprevention | Ovarian Cancer Chemoprevention | 261201500041I- 0-26100002-1 |
Benbrook, Doris M., Ph.D. | University of Oklahoma Health Sciences |
| Ovarian Cancer Chemoprevention | 261201500038I- 0-26100002-1 |
Benbrook, Doris M., Ph.D. | University of Oklahoma Health Sciences | ||
| Immunoprevention | Mesothelin Vaccination for the Prevention of Ovarian Cancer | 261201200014I- 0-26100002-1 |
Scholler, Nathalie, M.D., Ph.D. | SRI International | |
| Optimization and Further Development of Mesothelin Vaccine for the Prevention of Ovarian Cancer | 261201500041I- 0-26100003-1 |
Pipeline Project (Original Applicant: Scholler, Nathalie, M.D., Ph.D.) | Pipeline Project | ||
| Pancreas | Chemoprevention | Targeting P2X7 Receptor Antagonists for Prevention of Pancreatic Cancer | 261201200013I- 0-26100004-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences |
| Targeting CCK2R for Pancreatic Cancer Prevention | 261201200020I- 0-26100006-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | ||
| Preclinical Studies to Evaluate the Combination of Metformin and Aspirin for the Prevention of Pancreatic Cancer | 261201200013I- 0-26100010-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | ||
| Optimization of GEM Models for High-Risk Cohorts of Human Pancreatic Cystadenomas, IPMNs and PanINs Progression to PDAC | 261201500038I- 0-26100004-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | ||
| Immunoprevention | Development of Muc1 Vaccine for the Prevention of Pancreatic Cancer | 261201200013I- 0-26100005-1 |
Rao, Chinthalapally V., Ph.D. | University of Oklahoma Health Sciences | |
| Cancer Prevention by a-Enolase Vaccination | 261201500018I- 0-26100003-1 |
Novelli, Francesco, M.D. | University of Turin | ||
| Effects of a Multipeptide KRAS Vaccine in the Prevention of Pancreatic Cancer Driven by KRAS Oncoprotein | 261201500037I- 0-26100006-1 |
You, Ming, M.D., Ph.D. | Medical College of Wisconsin Cancer Center | ||
| Further Testing of a Multi-peptide KRAS Vaccine for Pancreatic Cancer Prevention | Pending | Pipeline Project (Original Applicant: You, Ming, M.D., Ph.D.) | Pipeline Project | ||
| Prostate | Chemoprevention | Chemoprevention of Prostate Cancer via Estrogen Receptor β Agonists | 261201200016I- 0-26100003-1 |
McCormick, David L., Ph.D., DABT | IIT Research Institute |
| Novel Androgen Receptor Antagonist-Mediated Chemoprevention of Prostate Cancer in Preclinical Model | 261201500042I- 0-26100002-1 |
McCormick, David L., Ph.D., DABT | IIT Research Institute | ||
| Preclinical Evaluation of a New Lipid-based SMDS BR-9001 Formulation | 261201500024I- 0-26100003-1 |
Zeligs, Michael, M.D. | BioResponse, LLC | ||
| Prostate Cancer Prevention by Aspirin and/or Other NSAIDs | 261201500038I- 0-26100005-1 |
Bosland, Maarten C., DVS, Ph.D. | University of Illinois | ||
| Preclinical Development of Chemopreventive agent 4-methylumbelliferone | N/A | Lokeshwar, Vinata, Ph.D. | Georgia Regents University | ||
| Preclinical Efficacy Evaluation of The Lipid-based SMDS Formulation of DIM, BR-9001 | 261201500042I- 0-26100003-1 |
Zeligs, Michael, M.D. | BioResponse | ||
| Immunoprevention | Preclinical Development of an RNA Vaccine for Immunoprevention of Prostate Cancer | Pending | Erasmus, Jesse, Ph.D. | HDT Bio Corp | |
| Other Cancers | Chemoprevention | Chemoprevention of endometrial hyperplasia and its transition to endometrial cancer with NSC 721689 | 261201500038I- 0-26100008-1 |
Benbrook, Doris M., Ph.D. | University of Oklahoma Health Sciences |
| Targeting the IL-6 Signaling Pathway as Chemopreventative Therapy for High-Risk Malignant Mesothelioma Populations | 261201500032I- 0-26100002-1 |
Menges, Craig, Ph.D. | Fox Chase Cancer Center | ||
| Oral Cancer Chemoprevention by Inhibitors of Inducible Nitric Oxide Synthase (iNOS) | 261201200016I- 0-26100002-1 |
McCormick, David L., Ph.D., DABT | IIT Research Institute | ||
| Chemoprevention of Esophageal Cancer by Targeting Multiple Pathways in a Mouse Model of Barrett's Esophagus | 261201500039I- 0-26100002-1 |
Wang, Timothy C., M.D. | Columbia University | ||
| Prevention of Hepatocellular Carcinoma (HCC) Associated with Non Alcoholic Steatohepatitis (NASH) | 261201500018I- 0-26100007-1 |
Beretta, Laura, Ph.D. | MD Anderson Cancer Center | ||
| A Dual AKT/PDPK1 Inhibitor for Actinic Keratosis and Skin Cancer Prevention | 261201500026I- 0-26100003-1 |
Kirkpatrick, Lynn D, Ph.D. | PHusis Therapeutics | ||
| Targeting STAT3 to Prevent Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH) | Pending | Tweardy, David J., M.D. | MD Anderson Cancer Center | ||
| Immunoprevention | A Polyvalent Vaccine Against Fusion Proteins Observed in Solid Tumors | 261201200018I- 0-26100006-1 |
Jaffee, Elizabeth M., M.D. | Johns Hopkins Kimmel Cancer Center | |
| GMP Production | Chemoprevention | Large Scale Synthesis of 9-cis-UAB30 to Support Translational Development of this Novel Chemopreventive Rexinoid | N/A | Muccio, Donald D., Ph.D. | University of Alabama at Birmingham |
| cGMP NSC 721689 Production for IRB-approved and NCI-funded Clinical Trials | N/A | Benbrook, Doris M., Ph.D. | University of Oklahoma Health Sciences | ||
| Immunoprevention | cGMP Production of a Chimeric Virus-like Particle Vaccine (RG1-VLP) for Prevention of HPV-Associated Cancers | N/A | Pipeline Project (Original Applicant: Kirnbauer, Reinhard, M.D.) | Pipeline Project | |
| Lowering the Risk of Lung and Other Cancers in High Risk Smokers using an Anti-nicotine Human mAb for Smoking Cessation | N/A | Kalnik, Matthew W., Ph.D. | Antidote Therapeutics, Inc. | ||
| Manufacture of a Vaccine Targeting Frame-Shift Mutations Characteristic of Tumors with Microsatellite Instability | 75N91019D00025- 0-759101900130-1 |
Pipeline Project (Original Applicant: Lipkin, Steven M., M.D., Ph.D., FACMG) | Pipeline Project |